Previous studies have reported that PD‐L1 expression may serve as a potential predictive biomarker for immunotherapy efficacy in SCLC.[26, 27] To further evaluate potential biomarkers for immunotherapy response in SCLC, we analyzed PD‐L1 tumor proportion score (TPS) in 72 available tumor specimens from the Shanzhong cohort (n = 222). The gene discussed is CD274; the disease is neoplasm.